Sobi Reports 2025 Revenue Growth and Sustainability Progress
Sobi reported 15% revenue growth to SEK 28 billion in 2025 while treating over 53,000 patients. The company published its Annual and Sustainability Report, highlighting pipeline advancements and transition to new sustainability reporting standards.
Swedish Orphan Biovitrum AB (Sobi) has published its Annual and Sustainability Report for 2025, outlining the company's progress in unlocking the potential of breakthrough innovations and therapies for people living with rare diseases. Revenue in 2025 grew by 15 percent at constant exchange rates to SEK 28 billion, while over 53,000 full-time equivalent patients were treated with a Sobi medicine during the year.
The report includes the audited Annual Report and Sobi's statutory Sustainability report, prepared in accordance with the Swedish Annual Accounts Act and the European Reporting Standards. It also incorporates Sobi's Task Force on Climate-related Financial Disclosures and EU Taxonomy reporting. Sobi's 2025 Sustainability Statement reflects the company's transition to the Corporate Sustainability Reporting Directive and the ESRS, with the structure and content aligned with new sustainability reporting requirements.
Sobi advanced its pipeline with the potential to change the standard of care in several rare and severe diseases. The company has a strong focus on building a sustainable business through collaboration and scientific expertise, ensuring that everyone eligible within its therapeutic areas has access to approved medicines.
Sobi is a global biopharma company with approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. The company's share is listed on Nasdaq Stockholm. The 2025 Annual and Sustainability Report is available on sobi.com, with the Swedish Annual Report also available in European Single Electronic Format.